Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTA018 in Stage 5 CKD with Secondary Hyperparathyroidism
NCT00742716Phase 2Completed
- Sponsor
- OPKO Health
- Start
- Oct 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of lunacalcipol in secondary hyperparathyroidism (SHPT) (4 arms), sponsored by OPKO Health. Primary endpoints: Pharmacokinetics of CTA018 Injection at Day 12 and Safety of CTA018 Injection. Started Oct 2008; status: completed.
02
Drugs
lunacalcipol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00742716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00742716.